108 related articles for article (PubMed ID: 17802728)
21. Allogeneic stem cell transplantation as treatment for myelofibrosis.
Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
[TBL] [Abstract][Full Text] [Related]
22. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
Finazzi MC; Lussana F; Salmoiraghi S; Spinelli O; Rambaldi A
Expert Rev Hematol; 2017 Jul; 10(7):627-636. PubMed ID: 28504024
[TBL] [Abstract][Full Text] [Related]
23. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
24. [The etiology, clinical features, and new therapy for primary myelofibrosis].
Shimoda K
Rinsho Ketsueki; 2006 Feb; 47(2):89-95. PubMed ID: 16529010
[No Abstract] [Full Text] [Related]
25. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.
Lee JM; Ahn A; Min EJ; Lee SE; Kim M; Kim Y
Blood Cancer J; 2023 Jun; 13(1):97. PubMed ID: 37365186
[No Abstract] [Full Text] [Related]
26. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
[TBL] [Abstract][Full Text] [Related]
27. Novel treatments to tackle myelofibrosis.
Zimran E; Keyzner A; Iancu-Rubin C; Hoffman R; Kremyanskaya M
Expert Rev Hematol; 2018 Nov; 11(11):889-902. PubMed ID: 30324817
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
29. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
30. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
32. Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis.
Kiss TL; Messner HA; Galal A; Lipton J
Bone Marrow Transplant; 2005 Jan; 35(2):213-4. PubMed ID: 15531899
[No Abstract] [Full Text] [Related]
33. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.
Pieri L; Guglielmelli P; Bogani C; Bosi A; Vannucchi AM;
Leuk Res; 2008 Mar; 32(3):516-7. PubMed ID: 17706283
[No Abstract] [Full Text] [Related]
34. Current treatment of myelofibrosis.
Silver R
Clin Adv Hematol Oncol; 2005 Apr; 3(4):269-70. PubMed ID: 16166999
[No Abstract] [Full Text] [Related]
35. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.
Shah MV; Patel KP; Luthra R; Kanagal-Shamanna R; Mehrotra M; Bachegowda LS; Champlin RE; Verstovsek S; Popat UR
Br J Haematol; 2018 Dec; 183(5):831-835. PubMed ID: 29265180
[No Abstract] [Full Text] [Related]
36. [Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way].
Merup M; Palmblad J
Lakartidningen; 2009 Dec 2-8; 106(49):3342, 3344-6. PubMed ID: 20104733
[No Abstract] [Full Text] [Related]
37. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis.
Robin M; Espérou H; de Latour RP; Petropoulou AD; Xhaard A; Ribaud P; Socié G
Br J Haematol; 2010 Sep; 150(6):721-4. PubMed ID: 20618333
[No Abstract] [Full Text] [Related]
38. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
[TBL] [Abstract][Full Text] [Related]
39. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI; Levine RL
Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
[TBL] [Abstract][Full Text] [Related]
40. Stem-cell transplantation for myelofibrosis.
Deeg HJ; Appelbaum FR
N Engl J Med; 2001 Mar; 344(10):775-6. PubMed ID: 11236794
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
